Golden Biotech Presents at 2024 BIO Asia Taiwan- “Creating the New Treatment Paradigm for Pancreatic Cancer”

Golden Biotechnology Corp. (GBC, GoldenBiotech, TPEx 4132), an advanced biopharmaceutical drug company, dedicating to bringing innovation and hope to patients with High Unmet Medical Needs. It's lead drug, Antroquinonol, an NCE with multi-functions and has completed many Phase 2 trials of treating the NSCLC, AML, Pancreatic Cancer and COVID-19. The Phase 2 trial results for the first-line treatment of metastatic pancreatic cancer showed significantly longer overall survival (mOS), and high safety profile in decreasing the hematologic adverse events than those from the trials of standard therapies. It has received the ODD (Orphan Drug Designation) from the FDA for treating AML, Pancreatic Cancer, and HCC, as well as the ODD for treating Pancreatic Cancer from the EU.
 
Join us at BIO Asia Taiwan 2024 and discover the latest breakthrough in our clinical trials for metastatic pancreatic cancer and other indications.
 
GoldenBiotech welcomes the inquiries and discussions from the partners for all the possible cooperation.
 
During the 2024 BIO Asia Taiwan, Golden Biotech will present at the “Company Presentation” section, also hold the following seminar:
Topic: "Insights into the Phase 2 Metastatic Pancreatic Cancer Study (Antroquinonol + Nab-Paclitaxel+ Gemcitabine)”  
Speakers: Boon-Kean Choy / General Manager and Dr. Penny Chen, MD / Medical Director
Time: 7/26 (Fr.), 11:30-12:20
Place: Room 506, Hall 1, 5th Fl., Taipei Nangang Exhibition Hall
Registration: https://reurl.cc/6v3EdO